Will Brown-Forman’s (BF.B) CEO Transition Test the Durability of Its 82-Year Dividend Streak?

Brown-Forman Corporation Class B

Brown-Forman Corporation Class B

BF.B

0.00

  • Earlier this week, Brown-Forman’s board approved a regular quarterly cash dividend of US$0.2310 per share on its Class A and Class B stock, payable on October 1, 2026 to shareholders of record on September 3, 2026, while stockholders re-elected directors, approved executive pay and ratified Ernst & Young as auditor at the annual meeting.
  • The dividend decision, which extends an 82-year run of quarterly payouts and 42 years of increases, comes just after long-serving CEO and President Lawson Whiting announced plans to retire once a successor is appointed, putting leadership succession and capital return stability at the center of investor focus.
  • We will now examine how Lawson Whiting’s planned retirement and the reaffirmed dividend record may shape Brown-Forman’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Brown-Forman Investment Narrative Recap

To own Brown-Forman, you generally need to believe its global spirits brands can keep earning solid cash flows despite softer earnings, weaker share price returns and rising health-conscious behavior. The key short term catalyst remains how effectively a new CEO maintains brand investment and execution. The biggest risk is that slowing spirits consumption in core developed markets and moderation trends weigh on volumes. This week’s CEO succession update and dividend affirmation do not materially change those near term drivers.

The most relevant recent announcement here is Brown-Forman’s decision in April to walk away from a potential combination with Pernod Ricard and focus on its own portfolio. For investors, that keeps the spotlight squarely on Brown-Forman’s ability to improve results from its existing brands at a time when earnings have declined year over year, developed markets look fragile, and the incoming CEO will inherit pressure to prove that organic execution can still support the long running dividend record.

Yet behind the comfort of an 82 year dividend record, investors should be aware of the growing risk that sustained moderation in alcohol consumption...

Brown-Forman's narrative projects $4.1 billion revenue and $811.1 million earnings by 2029. This requires 1.7% yearly revenue growth and roughly a $96 million earnings increase from $715.0 million today.

Uncover how Brown-Forman's forecasts yield a $28.02 fair value, a 7% upside to its current price.

Exploring Other Perspectives

BF.B 1-Year Stock Price Chart
BF.B 1-Year Stock Price Chart

Some of the lowest ranked analysts paint a much harsher picture, assuming revenue stuck near US$3.9 billion and 2029 earnings of about US$728 million, so you should recognize that their more pessimistic view of weaker alcohol demand and tighter regulation could look different once CEO succession and the latest dividend signal are fully reflected in updated forecasts.

Explore 6 other fair value estimates on Brown-Forman - why the stock might be worth as much as 48% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your Brown-Forman research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Brown-Forman research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Brown-Forman's overall financial health at a glance.

No Opportunity In Brown-Forman?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

  • AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
  • Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
  • This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.